Junge Zhang has bought OCGN on 5 days since Sep 2019

Junge (John) Zhang, PhD, is a director at Ocugen, Inc. (NASDAQ: OCGN) and the founder, president, and CEO of Biopeptek, a peptide-focused research and development company.( At Ocugen, he serves on the board of directors and participates in equity-based compensation programs; recent SEC Form 4 filings report his option exercises and grants related to Ocugen common stock, reflecting his status as a corporate insider and director.(

Dr. Zhang’s career spans senior scientific and leadership roles in the pharmaceutical industry, including nine years at the Janssen Pharmaceutical division of Johnson & Johnson, where he held multiple scientific and management positions and led development projects for three antibody drugs that ultimately received FDA approval.( Earlier, he was a senior chemist at Eisai USA, before founding Biopeptek in 2010 and building it into a company with more than 50 scientists and a state-of-the-art facility producing high-quality custom peptides for research and therapeutic uses.( He holds a Ph.D. in analytical chemistry from Drexel University, an M.S. in chemistry from the University of Louisiana, and a B.S. in materials science from Wuhan University of Technology in China, and he was born and raised in Qingdao, China before immigrating to the United States for graduate study.(

Written by Perplexity from public sources.